

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement appears for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.



UNITED GENE HIGH-TECH GROUP LIMITED

聯合基因科技集團有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock Code: 399)

THIRD SUPPLEMENTAL AGREEMENT CONCERNING EXTENSION OF LONG STOP DATE II IN RELATION TO THE VERY SUBSTANTIAL ACQUISITION AND CONNECTED TRANSACTION

Reference is made to the announcements of United Gene High-Tech Group Limited (the “**Company**”) dated 15 May 2013, 30 August 2013 and 20 November 2013 (the “**Announcements**”) and the circular of the Company dated 27 September 2013 (the “**Circular**”) in relation to, among others, the Transactions (as defined in the Announcements) and the announcements of the Company dated 2 August 2013, 23 August 2013 and 23 September 2013 in relation to the delay in despatch of the Circular (the “**Delay Announcement(s)**”). Capitalised terms used herein shall have the same meanings as those defined in the Announcements, Circular and the Delay Announcements unless defined otherwise.

THE THIRD SUPPLEMENTAL AGREEMENT

As disclosed in the Announcements, Completion II is conditional upon, among other things, the fulfillment of certain conditions precedent on or before Long Stop Date II, being 31 January 2014 (as amended by the second supplemental agreement dated 30 August 2013) or such other date as the Vendors and the Company may agree in writing.

Further, as disclosed in the Announcements, Completion II is conditional upon, among other things, the fulfillment of certain conditions precedent on or before Long Stop Date II, being 30 October 2013 or such other date as the Vendor A and the Company may agree in writing.

As additional time is required for the fulfillment of the said conditions precedent, on 28 January 2014 (after trading hours), the Vendors and the Company entered into the third supplemental agreement to the S&P Agreement (as amended and supplemented by the First Supplemental Agreement and a supplemental agreement dated 30 August 2013 (the “**Second Supplemental Agreement**”)), pursuant to which the Vendors and the Company agreed to extend Long Stop Date II to 30 April 2014 or such other date as Vendor A and the Company may agree in writing.

Save and except for the above, all other terms and conditions of the S&P Agreement, First Supplemental Agreement and Second Supplemental Agreement shall remain unchanged and continue in full force and effect.

Completion of the Transactions is subject to fulfillment of the conditions precedent as set out in the sections headed “Transaction I – Conditions precedent” and “Transaction II – Conditions precedent” in the Announcements. As the Transactions may or may not proceed, Shareholders and potential investors of the Company are advised to exercise caution when dealing in securities of the Company, and if they are in any doubt about their position, they should consult their professional advisers.

By Order of the Board
United Gene High-Tech Group Limited
Lee Nga Yan
Executive Director

Hong Kong, 28 January 2014

As at the date of this announcement, the Board comprises Ms. Jiang Nian (chairman & non-executive Director), Ms. Lee Nga Yan (executive Director), Dr. Guo Yi (executive Director), Ms. Xiao Yan (non-executive Director), Ms. Wu Yanmin (non-executive Director), Ms. Chen Weijun (independent non-executive Director), Dr. Zhang Zhihong (independent non-executive Director) and Mr. Wang Rongliang (independent non-executive Director).